Medical Therapy. Efficacy or Lack of Efficacy

Evaluation of therapeutic methods in high altitude pulmonary edema

Emilio Marticorena, Herbert N. HultgrenSan Marcos University and Chulec General Hospital. Palo Alto Veterans Administration Hospital and Stanford University School of Medicine. Peru and United States American Journal of CardiologyAm J Cardiol 1979; 43: 307-312DOI: 10.1016/s0002-9149(79)80020-x AbstractThe effect of treatment with bed rest alone was evaluated in 16 patients with high altitude pulmonary edema of mild […]

Evaluation of therapeutic methods in high altitude pulmonary edema Read More »

The Use of Treprostinil for Bronchopulmonary Dysplasia Associated Pulmonary Hypertension

Stephanie M. Tsoi, Claire Parker, Elizabeth Colglazier, Shannon Cheung, Mariam Taleb, Hythem Nawaytou, Elena Amin, Jeffrey R. Fineman, Roberta L. KellerUniversity of California San Francisco.United States Pediatric PulmonologyPediatr Pulmonol 2026; DOI: 10.1002/ppul.71448 AbstractBackground: Treprostinil for the treatment of bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH) has previously been described in small cohort studies, often used later in the course

The Use of Treprostinil for Bronchopulmonary Dysplasia Associated Pulmonary Hypertension Read More »

Safety of a novel portable inhaled nitric oxide generator for therapy of persistent pulmonary hypertension in neonates: a case series study

Yao Zhu, Jiongzhi He, Miner Cai, Lijun Wen, Minxu LiDongguan Maternal and Child Health Care Hospital. First Affiliated Hospital of Jinan University.China Translational PediatricsTransl Pediatr 2025; 14: 3305-3317DOI: 10.21037/tp-2025-535 AbstractBackground: Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening emergency in neonatal intensive care. Traditional treatments such as cylinder-based nitric oxide (NO) delivery systems rely on

Safety of a novel portable inhaled nitric oxide generator for therapy of persistent pulmonary hypertension in neonates: a case series study Read More »

Clinical impact of treprostinil in neonates with persistent pulmonary hypertension refractory to inhaled nitric oxide: A retrospective cohort study

Tae Hyeong Kim, Song Ee Youn, Sung-Hoon ChungKyung Hee University College of Medicine and Kyung Hee University Hospital at Gangdong.Republic of Korea MedicineMedicine 2026; 105: DOI: 10.1097/MD.0000000000046984 AbstractPersistent pulmonary hypertension of the newborn (PPHN) has limited options when unresponsive to inhaled nitric oxide (iNO). We evaluated the role of intravenous treprostinil and whether early response classification

Clinical impact of treprostinil in neonates with persistent pulmonary hypertension refractory to inhaled nitric oxide: A retrospective cohort study Read More »

High-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude

Bibhuti B. Das, Robert R. Wolfe, Kak-Chen Chan, Gary L. Larsen, John T. Reeves, Dunbar IvyChildren’s Hospital, Denver.United States Archives of Pediatric and Adolescent MedicineArch Pediatr Adolesc Med 2004; 158: 1170-1176DOI: 10.1001/archpedi.158.12.1170 AbstractBackground: Pulmonary hypertension has not been described as a predisposing risk factor for high-altitude pulmonary edema (HAPE) in children. Previous studies have shown an association

High-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude Read More »

Decreased endothelial cell retinoic acid signaling accelerates progression of single ventricle pulmonary arteriovenous malformations

Henry Rousseau, Tina Wan, Nhi Nguyen, Jaime Wendt Andrae, Michael Tschannen, Angela J. Mathison, Victor Jin, Olivia Groh, Xingyan Zhou, Stryder M. Meadows, Ramani Ramchandran,Igor Shmarakov, Amy Y. Pan, Andrew D. SpearmanMedical College of Wisconsin and Children’s Wisconsin. Rutgers University. Tulane University. United States bioRxivbioRxiv 2025; DOI: 10.64898/2025.12.08.693095 AbstractBackground: Pulmonary arteriovenous malformations (PAVMs) are vascular complications that

Decreased endothelial cell retinoic acid signaling accelerates progression of single ventricle pulmonary arteriovenous malformations Read More »

Interventions for preventing high altitude illness: Part 2. Less commonly-used drugs

Alejandro G Gonzalez Garay, Daniel Molano Franco, Víctor H Nieto Estrada, Arturo J Martí-Carvajal, Ingrid Arevalo-RodriguezNational Institute of Pediatrics.Mexico Cochrane Database of Systemic ReviewsCochrane Database Syst Rev 2018; 3: DOI: 10.1002/14651858.CD012983 AbstractBackground: High altitude illness (HAI) is a term used to describe a group of mainly cerebral and pulmonary syndromes that can occur during travel to elevations

Interventions for preventing high altitude illness: Part 2. Less commonly-used drugs Read More »

Reversible Pulmonary Hypertension in CblC Deficiency (MMACHC c.80 A>G): long-term outcomes of metabolic and PH-targeted therapy

Ruxuan He, Jinrong Liu, Xiaolei Tang, Hui Liu, Yuelin Shen, Xioayan Zhang, Huimin Li, Shunying Zhao, Haiming YangBeijing Children’s Hospital and Capital Medical University. Children’s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Hospital of Beijing Children’s Hospital and Seventh People’s Hospital of Xinjiang Uygur Autonomous Region.China Pediatric ResearchPediatr Res 2025; DOI: 10.1038/s41390-025-04720-8 AbstractBackground: Cobalamin C (cblC) deficiency,

Reversible Pulmonary Hypertension in CblC Deficiency (MMACHC c.80 A>G): long-term outcomes of metabolic and PH-targeted therapy Read More »

A prospective, multicenter, open-label, single-arm Phase 2 study to investigate the pharmacokinetics, safety, tolerability, and exploratory efficacy of selexipag in children with pulmonary arterial hypertension

Maurice Beghetti, Lene Nygaard Axelsen, Julian I. Borissoff, Mahdi Farhan, Simon Grill, Sining Leng, Alberto Russu, Catherine Lesage, Tatiana Remeňová, Shu-Fang Hsu Schmitz, Shahin MoledinaUniversity Hospitals of Geneva. Johnson & Johnson. Great Ormond Street Hospital. Switzerland and United Kingdom ChestChest 2025; DOI: 10.1016/j.chest.2025.12.013 AbstractBackground: Selexipag is an oral selective prostacyclin receptor agonist approved for treating pulmonary arterial

A prospective, multicenter, open-label, single-arm Phase 2 study to investigate the pharmacokinetics, safety, tolerability, and exploratory efficacy of selexipag in children with pulmonary arterial hypertension Read More »

Preparation of 18β-Glycyrrhetinic Acid Liposome and Its Therapeutic Effect on Pulmonary Arterial Hypertension

Yanmin Pei, Meidong Si, Xuemei Ma, Siyun Liu, Fang Zhao, Ru ZhouNingxia Medical University and General Hospital of Ningxia Medical University.China Drug Design, Development and TherapyDrug Des Dev Ther 2025; 19: 11119-11144DOI: 10.2147/DDDT.S547530 AbstractPurpose: 18β-Glycyrrhetinic acid liposomes (18β-GA-Lips) were developed to enhance lung-specific drug delivery and optimize the therapeutic management of pulmonary arterial hypertension (PAH).Methods: 18β-GA-Lips of varying

Preparation of 18β-Glycyrrhetinic Acid Liposome and Its Therapeutic Effect on Pulmonary Arterial Hypertension Read More »

Scroll to Top